Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.2K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

906
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
906
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

2.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

1.2K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
1.2K
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

573
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
573
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

83
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
83

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hybrid Surgical-Catheter Epicardial Ablation of Ventricular Tachycardia: A Case Series.

Journal of clinical medicine·2026
Same author

Incidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Near-field substrate analysis in ventricular tachycardia: a novel approach to identify the critical isthmus.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Insights Into the Natural History of Recurrent Myocarditis, A Multicenter International Study (Re-Myo Study).

Journal of the American Heart Association·2026
Same author

Right Ventricular Impairment Prevalence in Takotsubo Syndrome and Associated Clinical Characteristics and Outcomes: EVOLUTION Registry Results.

Radiology. Cardiothoracic imaging·2026
Same author

Evaluation and Management of Post-Cardiotomy Syndrome.

Methodist DeBakey cardiovascular journal·2026
Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026
Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026
Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026
Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026
Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026
Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026
See all related articles

Related Experiment Video

Updated: Nov 6, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.2K

Colchicine and the heart.

Massimo Imazio1, Mark Nidorf2

  • 1Cardiology, Cardiothoracic Department, University Hospital "Santa Maria della Misericordia", ASUFC, Piazzale Santa Maria della Misericordia 15, 33100 Udine, Italy.

European Heart Journal
|May 7, 2021
PubMed
Summary
This summary is machine-generated.

Colchicine, an anti-inflammatory drug, effectively reduces cardiovascular event recurrence in pericarditis and coronary syndromes. It is generally safe and well-tolerated for long-term cardiovascular disease management.

Keywords:
Acute coronary syndromeAtrial fibrillationChronic coronary syndromeColchicineCoronary artery diseaseHeart failureInflammasomePericarditis

More Related Videos

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts
08:51

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Published on: May 12, 2019

6.9K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.0K

Related Experiment Videos

Last Updated: Nov 6, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.2K
Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts
08:51

Intra-cardiac Side-Firing Light Catheter for Monitoring Cellular Metabolism using Transmural Absorbance Spectroscopy of Perfused Mammalian Hearts

Published on: May 12, 2019

6.9K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.0K

Area of Science:

  • Pharmacology
  • Cardiology
  • Inflammation Biology

Background:

  • Colchicine, an established anti-inflammatory agent for gout and familial Mediterranean fever, is increasingly recognized for its cardiovascular benefits.
  • Its mechanism involves modulating leukocyte function, cytokine expression, and neutrophil activity, impacting inflammatory pathways relevant to cardiovascular disease.

Purpose of the Study:

  • To review current evidence on the efficacy and safety of colchicine in managing cardiovascular conditions.
  • To highlight colchicine's role in preventing inflammatory flares in cardiovascular diseases.

Main Methods:

  • Systematic review of clinical trials and multicenter randomized controlled trials involving colchicine in cardiovascular patients.
  • Analysis of data from over 1600 patients with pericarditis and over 11,000 patients with coronary syndromes.

Main Results:

  • Colchicine significantly reduces recurrence risk by 50% in acute and recurrent pericarditis.
  • In acute and chronic coronary syndromes, colchicine demonstrated a >30% reduction in major adverse cardiovascular events, including CV death and myocardial infarction.
  • The drug is safe at doses of 0.5-1.0 mg daily, with good long-term tolerability in approximately 90% of patients.

Conclusions:

  • Colchicine is a safe and effective therapeutic option for reducing cardiovascular event recurrence in specific patient populations.
  • Its anti-inflammatory properties offer a valuable addition to standard care for managing inflammatory cardiovascular diseases like pericarditis and coronary syndromes.